|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang L, Parkin DM, Ferlay J, Li L and Chen
Y: Estimates of cancer incidence in China for 2000 and projections
for 2005. Cancer Epidemiol Biomarkers Prev. 14:243–250.
2005.PubMed/NCBI
|
|
3
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kajita E, Moriwaki J, Yatsuki H, Hori K,
Miura K, Hirai M and Shiokawa K: Quantitative expression studies of
aldolase A, B and C genes in developing embryos and adult tissues
of Xenopus laevis. Mech Dev. 102:283–287. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yao DC, Tolan DR, Murray MF, Harris DJ,
Darras BT, Geva A and Neufeld EJ: Hemolytic anemia and severe
rhabdomyolysis caused by compound heterozygous mutations of the
gene for erythrocyte/muscle isozyme of aldolase,
ALDOA(Arg303X/Cys338Tyr). Blood. 103:2401–2403. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kishi H, Mukai T, Hirono A, Fujii H, Miwa
S and Hori K: Human aldolase A deficiency associated with a
hemolytic anemia: Thermolabile aldolase due to a single base
mutation. Proc Natl Acad Sci USA. 84:8623–8627. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miwa S, Fujii H, Tani K, Takahashi K,
Takegawa S, Fujinami N, Sakurai M, Kubo M, Tanimoto Y, Kato T, et
al: Two cases of red cell aldolase deficiency associated with
hereditary hemolytic anemia in a Japanese family. Am J Hematol.
11:425–437. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Du S, Guan Z, Hao L, Song Y, Wang L, Gong
L, Liu L, Qi X, Hou Z and Shao S: Fructose-bisphosphate aldolase a
is a potential metastasis-associated marker of lung squamous cell
carcinoma and promotes lung cell tumorigenesis and migration. PLoS
One. 9:e858042014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ji S, Zhang B, Liu J, Qin Y, Liang C, Shi
S, Jin K, Liang D, Xu W, Xu H, et al: ALDOA functions as an
oncogene in the highly metastatic pancreatic cancer. Cancer Lett.
374:127–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng Y, Li X, Wu M, Yang J, Liu M, Zhang
W, Xiang B, Wang X, Li X, Li G, et al: New prognosis biomarkers
identified by dynamic proteomic analysis of colorectal cancer. Mol
Biosyst. 8:3077–3088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takashi M, Zhu Y, Nakano Y, Miyake K and
Kato K: Elevated levels of serum aldolase A in patients with renal
cell carcinoma. Urol Res. 20:307–311. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neely BA, Wilkins CE, Marlow LA,
Malyarenko D, Kim Y, Ignatchenko A, Sasinowska H, Sasinowski M,
Nyalwidhe JO, Kislinger T, et al: Proteotranscriptomic analysis
reveals stage specific changes in the molecular landscape of
clear-cell renal cell carcinoma. PLoS One. 11:e01540742016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He H and Magi-Galluzzi C:
Epithelial-to-mesenchymal transition in renal neoplasms. Adv Anat
Pathol. 21:174–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rivera MN and Haber DA: Wilms' tumour:
Connecting tumorigenesis and organ development in the kidney. Nat
Rev Cancer. 5:699–712. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Banumathy G and Cairns P: Signaling
pathways in renal cell carcinoma. Cancer Biol Ther. 10:658–664.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Caspi M, Perry G, Skalka N, Meisel S,
Firsow A, Amit M and Rosin-Arbesfeld R: Aldolase positively
regulates of the canonical Wnt signaling pathway. Mol Cancer.
13:1642014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tong X, Li K, Luo Z, Lu B, Liu X, Wang T,
Pang M, Liang B, Tan M, Wu M, et al: Decreased TIP30 expression
promotes tumor metastasis in lung cancer. Am J Pathol.
174:1931–1939. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng G, Wang S, Li X, Li S, Zheng Y,
Zhang L, Bao M, Liang C, Huang Z, Liu Y, et al: Positive expression
of NR6A1/CT150 as a predictor of biochemical recurrence-free
survival in prostate cancer patients. Oncotarget. 8:64427–64439.
2016.PubMed/NCBI
|
|
19
|
van Spronsen DJ, de Weijer KJ, Mulders PF
and De Mulder PH: Novel treatment strategies in clear-cell
metastatic renal cell carcinoma. Anticancer Drugs. 16:709–717.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Long F, Cai X, Luo W, Chen L and Li K:
Role of aldolase A in osteosarcoma progression and metastasis: In
vitro and in vivo evidence. Oncol Rep. 32:2031–2037. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Diehl JA: Cycling to cancer with cyclin
D1. Cancer Biol Ther. 1:226–231. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hill B, De Melo J, Yan J, Kapoor A, He L,
Cutz JC, Feng X, Bakhtyar N and Tang D: Common reduction of the Raf
kinase inhibitory protein in clear cell renal cell carcinoma.
Oncotarget. 5:7406–7419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Langner C, Ratschek M, Rehak P, Schips L
and Zigeuner R: Expression of MUC1 (EMA) and E-cadherin in renal
cell carcinoma: a systematic immunohistochemical analysis of 188
cases. Mod Pathol. 17:180–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rubinfeld B, Albert I, Porfiri E, Fiol C,
Munemitsu S and Polakis P: Binding of GSK3beta to the
APC-beta-catenin complex and regulation of complex assembly.
Science. 272:1023–1026. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kimelman D and Xu W: beta-catenin
destruction complex: Insights and questions from a structural
perspective. Oncogene. 25:7482–7491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taurin S, Sandbo N, Qin Y, Browning D and
Dulin NO: Phosphorylation of beta-catenin by cyclic AMP-dependent
protein kinase. J Biol Chem. 281:9971–9976. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hino S, Tanji C, Nakayama KI and Kikuchi
A: Phosphorylation of beta-catenin by cyclic AMP-dependent protein
kinase stabilizes beta-catenin through inhibition of its
ubiquitination. Mol Cell Biol. 25:9063–9072. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: Trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sattler M and Salgia R: The MET axis as a
therapeutic target. Update Cancer Ther. 3:109–118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grandori C, Cowley SM, James LP and
Eisenman RN: The Myc/Max/Mad network and the transcriptional
control of cell behavior. Annu Rev Cell Dev Biol. 16:653–699. 2000.
View Article : Google Scholar : PubMed/NCBI
|
